Acute Myocardial Infarction, Use of Percutaneous Coronary Intervention, and Mortality: A Comparative Effectiveness Analysis Covering Seven European Countries by Hagen TP et al.
ACUTE MYOCARDIAL INFARCTION, USE OF PERCUTANEOUS
CORONARY INTERVENTION, AND MORTALITY: A COMPARATIVE
EFFECTIVENESS ANALYSIS COVERING SEVEN EUROPEAN
COUNTRIES
TERJE P. HAGENa,*, UNTO HÄKKINENa,b, EVA BELICZAc, GIOVANNI FATOREd, FANNY GOUDEe
ON BEHALF OF THE EUROHOPE STUDY GROUP
aDepartment of Health Management and Health Economics, University of Oslo, Oslo, Norway
bCentre for Health and Social Economics, National Institute for Health and Welfare, Helsinki, Finland
cHealth Services Management Training Center, Semmelweis University, Budapest, Hungary
dCentre for Research on Health and Social Care Management, Bocconi University, Milano, Italy
eMedical Management Centre, Karolinska Institutet, Stockholm, Sweden
ABSTRACT
Percutaneous coronary interventions (PCI) on acute myocardial infarction (AMI) patients have increased substantially in the last
12–15 years because of its clinical effectiveness. The expansion of PCI treatment for AMI patients raises two questions: How did
PCI utilization rates vary across European regions, and which healthcare system and regional characteristic variables correlated
with the utilization rate? Were the differences in use of PCI associated with differences in outcome, operationalized as 30-day
mortality? We obtained our results from a dataset based on the administrative information systems of the populations of seven
European countries. PCI rates were highest in the Netherlands, followed by Sweden and Hungary. The probability of receiving
PCI was highest in regions with their own PCI facilities and in healthcare systems with activity-based reimbursement systems.
Thirty-day mortality rates differed considerably between the countries with the highest rates in Hungary, Scotland, and Finland.
Mortality was lowest in Sweden and Norway. The associations between PCI and mortality were remarkable in all age groups
and across most countries. Despite extensive risk adjustment, we interpret the associations both as effects of selection and treat-
ments. We observed a lower effect of PCI in the higher age groups in Hungary. Copyright © 2015 John Wiley & Sons, Ltd.
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1. INTRODUCTION
During the last 15 years, both percutaneous coronary intervention (PCI) and coronary artery bypass grafting
(CABG) have increasingly replaced medical therapies such as thrombolysis as the preferred treatment of acute myo-
cardial infarction (AMI) because of their clinical effectiveness (D’Errigo et al., 2010; Keeley et al., 2003). Further-
more, the share of AMI patients treated with PCI has increased, while the share of patients receiving CABG has
decreased during the same period (Lawesson et al., 2012; Nallamothu et al., 2007). Giving priority to PCI over
CABG for AMI patients is based on two arguments: ﬁrstly, PCI procedures are, in most cases, less costly than
CABG in the short run (Birim et al., 2012); secondly, the relative beneﬁts and harms of CABG versus PCI are even.
For patients with multivessel diseases, CABG is regarded as superior to PCI in the long run (Sipahi et al., 2014).
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This article addresses two questions related to the expansion of PCI treatment for AMI patients. First, how
did PCI utilization rates vary across European regions, and which healthcare system and regional characteristics
variables correlated with the utilization rates? Second, were the differences in use of PCI correlated with out-
come, operationalized as 30-day mortality? By analyzing these two questions within the same study, our aim is
to expand the understanding of the effects of different healthcare systems on procedure use and mortality in the
speciﬁc patient group that we analyzed.
In both parts of the analysis, we controlled for patients’ comorbidities and other relevant variables such as
the economic and demographic characteristics of the home regions of the patients. Our database covered nearly
100,000 AMI patients for the period of 2007–2009, residing in 110 regions in seven European countries.
We commence by a description of relevant aspects of the healthcare systems followed by a presentation of
the data, methods, and the results. Huge variations in both PCI rates and mortality across regions justify the
concluding discussion of funding systems and public health measures.
2. BACKGROUND AND THEORY
Many countries in the north and south of Europe departed from the social insurance model during the middle of
the 20th century and gradually implemented tax-based health insurance models. Although the social insurance
models and the tax-based models have basic ideas such as universal coverage and third-party payments in com-
mon, they also differ along several dimensions. In addition to the fundamentally different funding mechanisms,
taxes versus social health insurance contributions, dissimilarities exist, for example, regarding redistributional
efforts and the level of integration between payers and providers (Mossialos and Dixon, 2002). Alongside the
differences between the two models, we also observe dissimilarities within the models. One such difference is
the level of ﬁscal decentralization in the tax-based models. Another important difference is the type of
reimbursement system, in particular, the role and extent of activity-based funding (Street et al., 2011). In the
following, we discuss how healthcare system differences may affect our two dependent variables: utilization
rates (procedure intensity) for PCI and outcome measured by 30-day mortality.
2.1. Healthcare systems and utilization rates
Numerous studies have shown that the availability of PCI differs widely, according to both socioeconomic sta-
tus (Hetemaa et al., 2004; Rosvall et al., 2008; Salomaa et al., 2001) and ethnicity (Popescu et al., 2007).
Furthermore, differences in PCI rates were found in both private insurance-based and tax-based systems (Alter
et al., 1999; Bernheim et al., 2007; Rosvall et al., 2008; Widimsky et al., 2010). However, most of these
studies were based on data from periods where cardiac treatment facilities were less common and rationing con-
sequently harder. We conducted the current study on data from 2007–2009, a period where PCI facilities in
most European countries, and in all countries covered by this study, were well developed.
We investigated two healthcare system variables in explaining variation in PCI utilization rates: the type of
reimbursement system and the structure of the PCI facilities. Reimbursement systems are usually described
along two dimensions (Jegers et al., 2002): whether the system is retrospective or prospective and whether
the system is activity-based or ﬁxed. All seven countries applied prospective payment systems but some with
elements of cost compensation. In the Finnish system, for example, there have been examples of increases in
the prices that the regions set for the municipalities during a ﬁscal year. The following countries used
activity-based funding systems: Hungary, Italy, the Netherlands, and Norway. In particular, Hungary had a
strong activity-based component, as a speciﬁc fee-for-service (FFS) reimbursement for PCI procedures existed.
The Netherlands used diagnosis-related group (DRG)-based funding, while the Norwegian and the Italian
models combined activity-based funding based on the DRG system with risk-adjusted capitation. Finland
and Scotland used ﬁxed payment systems (global budgets). In Sweden, the reimbursement system differed
among the counties. We hypothesized that activity-based systems, in particular FFS, would lead to higher
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levels of PCI utilization than ﬁxed payment systems (Street et al., 2011). The mechanism is well understood
within both principal–agent theory (Laffont and Tirole, 1988) and theories of ﬁscal federalism (Inman,
1979). Activity-based funding will work as a price subsidy and, dependent upon how PCI is handled in the
DRG system, decrease the price–cost margin of using the procedures relative to other treatments. The price
effect is expected to be stronger in FFS systems (Hungary) than in DRG-based systems because the FFS-
component covers the cost of the procedure fully, while the DRG price covers the average cost of a hospital
stay for the speciﬁc patient group. In more of the countries, only a fraction of the DRG price is reimbursed.
The fact that access to PCI varies with distance to the services has formerly been found in Quebec, Canada,
while similar effects disappeared after control for socioeconomic status in Belgium and in the USA (Perelman
et al., 2009). A mechanism that may explain differences in access based on differences in distance is that phy-
sicians will hesitate to send old, frail patients for PCI treatment if the distances are too long because of fear of
complications. The structure of PCI facilities differed widely across the countries in the current study: Norway
and Scotland stood out with very centralized structures, while Finland and Sweden had a decentralized struc-
ture. The other countries were located between these extremes.
2.2. Procedure intensity and mortality
In the second step of our analysis, we investigated the association between the use of PCI and mortality. The aver-
age clinical effectiveness of invasive procedures such as PCI relative to medical treatment is well documented in
clinical trials. In a review by Keeley et al. (2003), when compared with in-hospital thrombolytic therapy, PCI
lowered mortality from 9% to 7% after 4–6 weeks, a relative reduction of 25%. Results from real-life data are less
clear, particularly in the higher age groups. An early six-country comparative study found wide variation in the use
of invasive procedures, while mortality was similar in all countries (Yusuf et al., 1998). A more recent study com-
paring two metropolitan areas in the USA and Sweden, with signiﬁcant differences in procedure intensity, con-
cluded differently, as a marked positive effect of PCI on long-term survival was found (Smith et al., 2013).
Likewise, a nationwide study using Swedish and British patient registers indicated that higher levels of both primary
PCI and beta-blockers contributed to the lower mortality ratios that were found in Sweden (Chung et al., 2014).
In this article, we expanded the comparative analysis of the association between PCI and mortality to include
a subgroup analysis restricted to patients aged more than 84 years old. It has previously been shown that the
primary success rate of PCI at older ages is lower than for younger ages (Kala et al., 2012). In line with most
former studies, we hypothesized that the statistical effect of PCI was positive, but with diminishing return, in
the higher age groups.
3. DATA AND METHODS
3.1. Data
The AMI national databases included patients from the national discharge registers hospitalized for AMI
(International Classiﬁcation of Diseases – ICD10: I21–I22 or ICD9: 410). For the development of the data-
bases, we used a common protocol and linked data from the discharge registers to data from other national rou-
tinely collected data covering drug utilization and deaths (Belicza et al., 2014a; Hakkinen et al., 2013). We
excluded patients if they had a known hospital admission with a main diagnosis of AMI within 365 days prior
to the index admission, the length of their stay during their ﬁrst admission was more than 60 days, their age was
below 40 or above 85 years (however, we also included patients of 85 years and above in a separate analysis),
they had no national ID number or known place of residence in their own country, or they died within 2 days
following the index admission (see succeeding text).
We used patient-level data in the international comparative database for all countries except Scotland and
the Netherlands, where only data aggregated to a regional level were available because of national data
regulations. The patient-level data were from 2007 to 2008 in Finland, Hungary, Italy, and Sweden, and from
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2009 in Norway. The regional analysis was conducted using data from 2007 in Finland, Hungary, Italy, the
Netherlands, Scotland, and Sweden, and from 2009 in Norway.
3.2. Variable deﬁnitions
We deﬁned four dependent variables. In the patient-level analysis, receiving PCI within 2 days (2D_PCI) was
described by a dummy variable taking the value of 1 if the patient received PCI on the admission day or on the
next day, 0 otherwise. In the regional analyses, which also included data from Scotland and the Netherlands, we
deﬁned the dependent variable (2D_PCIR) as the share of patients treated with PCI within 2 days. In the patient-
level analysis, we deﬁned the outcome as 30-day mortality (30D_M). 30D_M took the value of 1 if the patient
died within 30 days from the index day, and 0 otherwise. We included all causes of death. In the regional
analyses, we deﬁned the 30-day mortality rate (30D_MR) as the share of patients who died within 30 days
(Moger and Peltola, 2014). In all analyses using patient-level data, we excluded patients who died within the ﬁrst
2 days, because survival in this period was a premise for receiving PCI. In the regional-level analyses, we stan-
dardized the dependent variables (2D_PCIR and 30D_MR) by age and sex before running the regressions.
We divided the independent variables into two groups. The ﬁrst group included the individual variables:
age, gender, and a list of comorbidities. We categorized all variables. For the comorbidities, we included indi-
cators on whether the comorbidity was present or not based on: (i) hospital admissions with comorbidity as the
main or secondary diagnosis during the period 365 days prior to the index admission; or (ii) medication pur-
chases for comorbidity during the 365 days prior to the index admission. We included a variable describing
the length of hospital stay during the previous year (LOSPY), for additional risk adjustment.
The second group of variables included regional-level data. In the analyses of PCI utilization, we included
variables describing the reimbursement system and the structure of the PCI facilities. We described the
reimbursement system by dummy variables, using ﬁxed payment systems as a reference category: DRG-based
payment system (DRG-based) and FFS (FFS-based). In an alternative speciﬁcation, we grouped DRG-based
and FFS together and formed the variable ABF, still with ﬁxed payment systems as a reference. Based on initial
analyses, we chose the number of catheterization labs per 100,000 inhabitants to describe the structure of the ser-
vices (CATH_LABS). Demand side variables included gross domestic product (GDP) per capita (logGDP_CAP),
size of the population (logPOP), population density (logPOPDENS), education level for men (EDU_MALE),
unemployment rate (UNEMPL), and the share of the population aged 70–85 years (SHARE70). Initially, we also
tested a variable describing the educational level among women. This variable performed worse than the compa-
rable variable for men andwas dropped because of colinearity problems. As indicated, we log transformed some of
the variables because of the assumption of marginally decreasing effects. The deﬁnitions of the comorbidity
variables can be found in Häkkinen et al. (2013) and descriptive statistics for age, sex, and comorbidities inMoger
and Peltola (2014). We present descriptive statistics for the regional variables in Table I.
3.3. Regression analyses
We estimated multilevel models with regions and patients deﬁning the levels. In addition to the usual individual
error terms, the model contained random effects for regions. These region-speciﬁc effects allowed for depen-
dence between observations of patients within the region. Let qij be the binary outcome for the jth patient
treated in the ith region, with qij=1 if the patient died or received PCI, 0 otherwise. The random effects model
can then be formulated, for example, by following Ash et al. (2011):
qijjβ0; β; xij; ai∼Bernoulli pij
 
; where ln
pij
1 pij
¼ β0 þ x′ijβþ ai; (1)
where xij is a vector of patient-speciﬁc characteristics. We assumed that the outcome would follow a logit model,
given the region effect ai. The latter is a priori assumed to follow a normal distribution ai σj 2a∼N 0; σ2a
 
.
The main advantage of the random effect model is that it permits the inclusion of regional-level covariates,
which cannot easily be included in a ﬁxed-effect model, which would be an alternative to modeling the regional
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effects. We treated the country effects as ﬁxed. To test the effects of reimbursement systems, we replaced the
ﬁxed-effect variable for countries with ﬁxed-effects variables describing the reimbursement systems
(DRG-based and FFS-based) in one of the speciﬁcations and ABF in another.
In the regional analyses, we analyzed 2-day PCI rate (2D_PCIR), which was standardized1 for age and sex.
The basic regression equation of regional PCI rates was
2D_PCIR ¼ β0 þ β1Rr þ εc (2)
where r denoted the region, R was a vector of the regional variables mentioned earlier, and εc was a country
variable. As in the patient-level analyses, we included the country-level variables and, alternatively, variables
describing the reimbursement systems as ﬁxed effects.
In the patient-level analyses of 30-day mortality (30D_M), we included 2D_PCI as an independent variable,
in addition to the random effects regional variables and ﬁxed-effects variables for the country. In a separate re-
gression, we analyzed the marginal effects of increasing the PCI rate in the higher age groups.
In the patient-level analysis, we applied effect coding to country variables in which the reference (that is, odds
ratio) is the grand mean of the sample. In the regional-level analyses, the coefﬁcients of the country variables
describe how many percentage points the PCI rate or 30-day mortality differs from the average of all countries.
3.4. Instrument variables
It is obvious that selection of patients for PCI is related to expected health outcomes including variation in
expected mortality. The causal relationship between mortality and PCI may therefore work in both ways. This
can be taken into account by a two-stage estimation method (Terza et al., 2008) with instrumental variables
(Hakkinen et al., 2014; Stargardt et al., 2014). Unfortunately, our data do not include good instruments such as
distance to a hospital with PCI capacity (Newhouse and McClellan, 1998). However, we conducted sensitivity
analysis using the hospital-level 2-day PCI rate for unstable angina as an instrument. The instrument variable
described procedure intensity for patients suffering from similar, but different, conditions requiring similar
treatments (Hakkinen et al., 2014). The F-statistics of the instrument exceeded 10 (a usually assumed threshold)
in all models.
4. RESULTS
4.1. Percutaneous coronary intervention utilization
The age-standardized and sex-standardized PCI rates were highest in the Netherlands (43.4%), followed by
Sweden (42.8%) and Hungary (39.5%). The PCI rate was lowest in Scotland (17.9%) (Figure 1 and Table I).
The differences between the countries were lower for 30 days of PCI than for 2 days of PCI (ﬁgures not
shown), indicating higher variation in the acute phase of AMI treatment than in the overall supply of services.
The intracountry regional variation measured by the coefﬁcient of variation at the regional level was highest in
Scotland (37.8) and lowest in the Netherlands (17.7) (Table I).
The probability of receiving PCI within 2 days decreased with age and with having comorbidities
(ﬁgures not shown), in particular, by cardiac insufﬁciency (heart failure) and mental disorders. The proba-
bility of receiving PCI also decreased with the patient’s length of stay last year (LOSPY) and was lower for
women than for men in all countries (Table II, M5a–e). Sex differences were lowest in Hungary and
Finland.
The number of catheterization labs per 100,000 inhabitants varied from 0.09 in Scotland (5 out of 12
regions had catheterization labs) and 0.11 in Norway (6 out of 20 regions had catheterization labs) to 0.69
1Only age-standardized and sex-standardized ﬁgures were used because we did not have comparable data on comorbidity from Scotland
and the Netherlands.
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in Finland where all regions had labs (Table I). The number of catheterization labs per 100,000 inhabitants at
the level of regions had signiﬁcant positive effects on the probability of receiving PCI across all speciﬁcations,
except for the country analyses in Finland and Italy (Table II, M3–M5a–e). We also found a positive statistical
effect of population size. Neither GDP per capita nor the other regional variables had signiﬁcant statistical
effects.
In models M6–M9 (Table II), we aggregated all patient-level data to the regional level and added data from
Scotland and the Netherlands to the analyses. The analyses on the more comprehensive regional dataset
conﬁrmed the main ﬁndings from the patient-level data, as the number of catheterization labs per 100,000
inhabitants and the size of the population were associated with increased PCI rates. Replacing the country
ﬁxed-effects with ﬁxed-effects variables describing the reimbursement system (M2, M4, M7, and M9) indi-
cated that the countries with global budgets had a signiﬁcantly lower PCI rate than average. In a separate spec-
iﬁcation (ﬁgures not shown), we tested the effects of the two activity-based reimbursement systems, the FFS
system, and the DRG-based systems, against the effects of global budgets. The activity-based systems had,
after controlling for the regional-level variables, a 17% higher PCI utilization rate than the countries with global
budget systems (p<0.01). As Hungary was the only country with FFS, it was not possible to distinguish the
country effect from the statistical effect of the reimbursement system.
4.2. Thirty-day mortality
Age-standardized and sex-standardized 30-day mortality rate (30D_MR) differed considerably between the
countries (Table I and Figure 2) and were highest in Hungary (18.2%), followed by Scotland (14.0%) and
Finland (10.6%). We found the lowest rates in Sweden (7.2%) and Norway (5.5%). The pattern of 365-day
mortality (ﬁgures not shown) were similar to 30-day mortality but with lower country differences. Regional
variations were highest in Scotland (coefﬁcient of variation = 23.3).
Thirty-day mortality was higher than the average in older age groups and was lower for women than for men
for all countries except Norway (Table III, M1–M2a–e). We found excess mortality rates for several of the co-
morbidities, in particular, for cardiac insufﬁciency, diabetes mellitus, cancer, and mental disorders (data not
shown). In the individual-level analyses, patients treated with PCI had a reduced probability of death within
30 days by approximately 60% but with remarkable variations between the countries. The effects were weakest,
but still high, in Hungary and Italy (Table III). The 2-day PCI rates were negatively associated with death rate
in the regional-level analyses, but the effects were not signiﬁcant. There can be several reasons for the
Figure 1. Two-day percutaneous coronary intervention (PCI) rate, standardized for age and sex (regional point estimates with standard
deviation)
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insigniﬁcant statistical effects in the regional analyses, for example, that the marginal effect of PCI varies
between countries (Skinner, 2011). Of the regional variables, unemployment rate was associated positively
on mortality in the analysis of the full sample and in Sweden (Table III, M1 and M2e).
We investigated the somewhat lower effects of PCI on 30-day mortality in Italy and Hungary, and the higher
effects of PCI in Finland, further in age-speciﬁc analyses (Table IV). We suspected that the marginal effects of
PCI were lower in the higher age groups than in the lower and that the marginal effects were particularly low in
the higher age groups in countries with high PCI rates.
As in the former analyses, the probability of dying within 30 days was approximately 60% lower for those
that received PCI than for those who did not across all age groups (Table IV, models with no interactions). Con-
trary to our expectations, the effects of PCI were as high in the higher age groups (75–84 years and 85 years and
over) as in the lower age groups (40–59 and 60–74 years). Neither did we ﬁnd a stable diminishing effect of the
PCI rate. However, we observed a relatively low effect of PCI in the age group of 75–84 years in Hungary and
Italy. Sweden, however, had a PCI rate for this age group as equally high as Hungary and Italy (0.27 in Sweden
compared with 0.27 in Hungary and 0.23 in Italy - ﬁgures not reported in tables) and combined it with low
mortality.
Table II. Variation in 2-day PCI utilization
Individual-level data (2D_PCI), odds ratios (Wald)
M1 M2 M3 M4 M5a M5b
Full sample Full sample Full sample Full sample Finland Hungary
Male 1.311*** (17.47) 1.311*** (17.47) 1.311*** (17.48) 1.311*** (17.47) 1.117* (2.51) 1.196*** (6.08)
LOSPY 0.983*** (15.33) 0.983*** (15.33) 0.983*** (15.33) 0.983*** (15.32) 0.963*** (8.62) 0.988*** (6.07)
Finland 0.872 (1.18) – 0.860 (0.91) – – –
Hungary 1.464*** (3.35) – 1.163 (0.60) – – –
Italy 0.600** (2.80) – 0.483*** (3.50) – – –
Netherlands – – – – – –
Norway 0.953(0.42) – 1.289 (1.17) – – –
Scotland – – – – – –
Sweden 1.371** (2.82) – 1.607** (2.78) – – –
REIMB_DRG – 0.915 (0.92) – 0.788 (1.57) – –
REIMB_FFS – 1.281* (2.48) – 1.504 (1.89) – –
REIMB_GLOB – 0.853 (1.90) – 0.843 (1.30) – –
CATH_LABS – – 1.010*** (4.52) 1.009*** (4.21) 0.999 (0.26) 1.023*** (5.04)
LogGDP – – 0.603 (1.41) 0.611 (1.36) 0.976 (0.02) 0.624 (0.98)
LogPOP – – 1.362** (3.12) 1.375** (3.18) 1.499 (1.43) 1.189 (0.82)
LogPOPDENS – – 1.062 (1.00) 0.924 (1.53) 0.782 (1.45) 1.991* (2.53)
EDU_MALE – – 1.005 (0.44) 1.039*** (4.25) 1.034 (0.96) 0.885 (1.86)
UNEMPL – – 0.951 (1.67) 0.945 (1.94) 0.952 (0.69) 0.956 (1.67)
SHARE70 – – 0.963 (1.00) 0.983 (0.51) 1.045 (0.66) 1.004 (0.05)
Intercept – – – – – –
Age variables Included Included Included Included Included Included
Comorbidity
variables
Included Included Included Included Included Included
N (patients) 98008 98008 98008 98008 14134 23820
N (regions) 86 86 86 86 19 20
Rho 0.08 0.09 0.05 0.06 0.05 0.02
AIC
Sigma_u 0.53 0.58 0.42 0.45 0.41 0.25
Ll 58241.46 58247.82 58220.81 58227.70 7766.60 14758.17
PCI, percutaneous coronary interventions; 2D_PCI, receiving PCI within 2 days; 2D_PCIR, share of patients treated with PCI within 2 days;
LOSPY, length of hospital stay during the previous year; REIMB_DRG, reimbursement for diagnosis-related group; REIMB_FFS, fee-
for-service reimbursement; REIMB_GLOB, reimbursement for global budgets; CATH_LABS, structure of the services; LogGDP, gross
domestic product; LogPOP, size of the population; LogPOPDENS, population density; EDU_MALE, education level for men; UNEMPL,
unemployment rate; SHARE70, share of the population aged 70–85 years, AIC; Akaike Information Criterion, LI; Loglikelihood.
aThe dependent variable is standardized by age and sex.
*Signiﬁcant at 10% level;
**signiﬁcant at 5% level; and
***signiﬁcant at 1% level.
Results from individual-level (logistic regression models) and regional-level analyses (linear regression models).
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4.3. Sensitivity analysis
In most cases, the two-stage estimation with the instrument did not change the effect of PCI rate on 30-day mortality
and country ordering as reported in Tables III and IV. In Hungary (0.40) and Sweden (0.27), the odds ratios were
Table II. (Continued)
Individual-level data (2D_PCI), odds ratios (Wald)
Regional-level data (2D_PCIR), regression coefﬁcients
(t-values)a
M5c M5d M5e M6 M7 M8 M9
Italy Norway Sweden Full sample Full sample Full sample Full sample
Male 1.472*** (9.85) 1.378*** (5.54) 1.429*** (13.80) – – – –
LOSPY 0.988*** (3.39) 0.977*** (5.18) 0.984*** (8.93) – – – –
Finland – – – 0.045 (1.04) – 0.008* (1.74) –
Hungary – – – 0.052 (1.21) – 0.045 (0.80) –
Italy – – – 0.039 (0.74) – 0.079 (1.48) –
Netherlands – – – 0.128*** (2.76) – 0.080* (1.69) –
Norway – – – 0.018 (0.41) – 0.086* (1.68) –
Scotland – – – 0.159*** (3.45) – 0.125*** (2.71) –
Sweden – – – 0.045*** (1.05) – 0.075* (1.68) –
REIMB_DRG – – – – 0.040 (1.01) – 0.052 (0.87)
REIMB_FFS – – – – 0.027 (0.66) – 0.038 (0.069)
REIMB_GLOB – – – – 0.068* (1.71) – 0.090* (1.70)
CATH_LABS 0.941*** (6.09) 1.012* (2.00) 1.016*** (3.47) – – 0.193*** (4.07) 0.162*** (3.89)
LogGDP 3.537e + 11*** (8.61) 0.234* (2.43) 0.235 (1.58) – – 0.016 (0.31) 0.035 (0.70)
LogPOP 0.226*** (4.05) 1.670** (2.84) 1.420* (2.30) – – 0.039** (2.07) 0.056*** (2.78)
LogPOPDENS 0.364*** (4.70) 1.032 (0.27) 0.998 (0.02) – – 0.014 (1.31) 0.001 (0.12)
EDU_MALE 0.658* (2.57) 0.992 (0.47) 0.995 (0.16) – – – –
UNEMPL – 0.500** (2.99) 0.910 (1.05) – – – –
SHARE70 – 0.746*** (3.45) 0.948 (0.42) – – 0.090 (1.12) 0.010 (0.13)
Intercept – – – 0.342*** (8.94) 0.365*** (9.47) 0.109 (0.18) 0.769 (1.25)
Age variables Included Included Included Not included Not included Not included Not included
Comorbidity
variables
Included Included Included Not included Not included Not included Not included
N (patients) 17,007 8,046 35,001 – – – –
N (regions) 6 19 21 110 110 110 110
Rho 0.00 0.02 0.03 – – – –
AIC 141.7 125.3 149.9 129.8
Sigma_u 0.00 0.26 0.32 – – – –
Ll 9979.88 4602.51 20793.22 – – – –
Figure 2. Thirty-day mortality, standardized for age and sex (regional point estimates with standard deviation)
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even smaller compared with the estimation results from the model in which PCI was assumed to be exogenous
(Table III). In Italy, the effect was clearly smaller (0.82). Similar trends existed also in the age group speciﬁc results.
5. DISCUSSION
The use of PCI on AMI patients has increased substantially in the last 12–15 years because of the procedure’s
clinical effectiveness. This article has addressed two questions related to the expansion of PCI treatment for
AMI patients. First, how did PCI utilization rates vary across European regions, and which healthcare system
and regional characteristic variables correlated with the utilization rates? Second, were the differences in use of
PCI associated with outcome, operationalized as 30-day mortality?
Although we analyzed variation in a period in which PCI facilities were well developed (2007–2009), we
found large variations in PCI utilization rates both across and within countries. PCI rates were highest in the
Netherlands, followed by Sweden and Hungary. Within countries, regional variation was highest in Scotland.
We investigated the associations between two healthcare system variables and PCI utilization rates: the struc-
ture of the PCI facilities and the type of reimbursement system. Both variables affected the probability of re-
ceiving PCI. The probability of receiving PCI was highest in regions with high catheterization capacity. The
weaker statistical effects of this variable in Finland and Italy probably reﬂected that all regions had PCI facil-
ities and that the regional variation consequently became small (the data from Italy covered only six regions, all
located in metropolitan areas). The statistical effect of reimbursement systems was also strong. The regions
with (partly) activity-based reimbursement systems had a 17% higher PCI rate than global budgeting systems.
Two limitations in the analyses of PCI rates should be mentioned. Firstly, the operationalization we have
chosen with the use of dummy variables describing reimbursement systems will partly capture country
differences because only one of the countries (Sweden) has regional variation on this variable. Secondly,
PCI can be handled differently in the DRG systems across the countries. We do not have information that
describes these differences.
Thirty-day mortality rate differed also considerably between the countries with the highest rates in Hungary,
followed by Scotland and Finland. Mortality was lowest in Sweden and Norway. Regional variations were
highest in Scotland. Receiving PCI was, together with age and comorbidities, a strong predictor of
individual-level mortality. After risk adjustments, receiving PCI reduced the probability of 30-day mortality
by approximately 60%. Despite the extensive risk adjustment, we interpreted the effect as a combination of se-
lection and treatment effects. Our use of instrumental variables did not seem to reduce the selection problem.
We considered other alternatives, but the most relevant alternative with the use of distances from home to hos-
pital as instrument was not available for our study. The regional-level analyses indicated weaker associations.
Regions with higher PCI rates had lower mortality rates but the statistical effect was insigniﬁcant.
The effects of PCI on mortality on individual level were manifest in all age groups and across most of the
countries. However, we did observe a lower association between PCI and mortality in the age group of
75–84 years in Hungary, and partly in Italy, than in the other countries. A cost-effectiveness study is beyond
the scope of this paper, but the ﬁndings motivate a further investigation into the relationship between the
FFS system, the PCI rate, and the mortality rate in Hungary. The high AMI mortality rate in Finland was also
surprising as it deviated signiﬁcantly from the neighboring Nordic countries. A possible explanation may be
related to the lack of acute services at more of the Finnish central hospitals during nighttime. This ﬁnding needs
further investigation as well.
Our results were obtained from a large dataset based on the administrative information systems of entire
populations of seven European countries. While the dataset did not contain all the variables to fully control
for confounding, to our knowledge, it is the largest patient-level dataset on the use of PCI and its association
with 30-day mortality. It conﬁrms widely unexplained variations in PCI intervention rates. It also conﬁrms that
patients receiving PCI have lower mortality, thus providing real-life evidence of the effectiveness of this
intervention.
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